Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;125(2):469-476.e2.
doi: 10.1016/j.jaci.2009.09.054.

Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis

Affiliations

Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis

Heather Osterfeld et al. J Allergy Clin Immunol. 2010 Feb.

Abstract

Background: The cytokine IL-9 has been implicated in allergic reactions, including food allergy, but its contribution to parenteral versus oral antigen-induced anaphylaxis remains unclear.

Objectives: We sought to delineate the contribution of the IL-9/IL-9 receptor alpha-chain (IL-9R) pathway to parenteral and oral antigen-induced anaphylaxis.

Methods: Wild-type, IL-9-deficient (Il9(-/-)), and IL-9R-deficient (Il9R(-/-)) mice were subjected to passive and active parenteral and oral antigen (ovalbumin [OVA])-induced anaphylaxis. Severity of systemic anaphylaxis was gauged by decreased body temperature; intestinal anaphylaxis was assessed based on secretory diarrhea, intestinal mastocytosis, and serum murine mast cell protease 1 level. Specific immunoglobulin isotypes or immunoglobulin receptor-blocking antibodies were administered before challenge to define the role of the IgE and IgG pathways.

Results: Repeated oral antigen challenge of OVA-sensitized wild-type mice induced anaphylaxis with both systemic and intestinal involvement; both were IgE dependent and attenuated in Il9(-/-) and Il9R(-/-) mice. In contrast, parenteral OVA challenge of OVA-sensitized wild-type mice induced systemic anaphylaxis, which was independent of the IL-9/IL-9R pathway. Strikingly, the IL-9/IL-9R pathway had no role in either the IgG or IgE component of parenteral antigen-induced or anti-IgE and anti-FcgammaRII/III mAb-induced systemic anaphylaxis.

Conclusions: Parenteral antigen-induced murine systemic anaphylaxis is mediated by both IgG- and IgE-dependent pathways, and both can occur independently of IL-9/IL-9R signaling. In contrast, oral antigen-induced intestinal and systemic anaphylaxis is strictly IgE mediated and requires IL-9/IL-9R signaling. These studies indicate differential involvement of the IL-9/IL-9R pathway in systemic and oral antigen-induced anaphylaxis.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: F. D. Finkelman is a consultant for Abbott and Associate Editor for the Journal of Allergy and Clinical Immunology, has received research support from Abbott, and is treasurer-elect for the American Association of Immunologists. The rest of the authors have declared that they have no conflict of interest.

Figures

FIG 1
FIG 1
Critical role for the IL-9/IL-9R pathway in anaphylaxis induced by oral antigen challenge. A, Diarrhea occurrence in vehicle (Veh)– or OVA-sensitized intragastric (i.g.) OVA-challenged WT, Il9R2/2, and Il92/2 mice. A and B, Serum mouse mcpt-1 levels (Fig 1, B) and temperature change (Fig 1, C) from 0 to 60 minutes after the sixth intragastric vehicle or OVA challenge in OVA-sensitized WT, Il9R2/2, and Il92/2 mice. Data in Fig 1, A, are represented as a percentage of diarrhea occurrence after a number of OVA challenges. The fraction indicates the number of mice with diarrhea out of the total number of mice in that group. Data in Fig 1, B and C, are representative after the sixth intragastric vehicle or OVA challenge in OVA-sensitized WT, Il9R2/2, and Il92/2 mice. Fig 1, B, Four to 8 mice per group from n = 3 experiments. *P < .05. Fig 1, C, Individual symbols represent 1 mouse. *P < .001.
FIG 2
FIG 2
No role for the IL-9/IL-9R pathway in anti-IgE–mediated passive systemic anaphylaxis. A, Rectal temperature in control immunoglobulin (Ig)– and anti-IgE–treated WT, Il92/2, and Il9R2/2 mice. Total IgE levels (B) and mast cells per high-power field (HPF) in the tongue (C), ear skin (D), and small bowel (E) in control Ig– and anti-IgE–treated WT, Il92/2 and Il9R2/2 mice. F, Serum mcpt-1 concentrations in control Ig and anti-IgE mAb–challenged WT, Il92/2, and Il9R2/2 mice. Fig 2, A and F, n = 3 to 7 mice per group. *P < .05 compared with WT control Ig–treated mice. Fig 2, C through E, n = 4 mice per group. Fig 2, B, n = 4–6 mice per group from duplicate experiments. n.s., Not significant. OD; optical density.
FIG 3
FIG 3
No role for the IL-9/IL-9R pathway in anti-FcgRII/III–mediated passive systemic anaphylaxis. A and B, Total IgG1 and IgG2a levels in WT, Il92/2, and Il9R2/2 mice. C, Rectal temperature response of WT, Il92/2, and Il9R2/2 mice to intravenous injection of anti-FcgRII/III mAb or control immunoglobulin (control Ig; J1.2). Fig 3, A and B, n = 4 mice per group from duplicate experiments. Fig 3, C, n = 5–11 mice per group. *P < .05 compared with WT control mice.
FIG 4
FIG 4
No role for the IL-9/IL-9R pathway in parenteral antigen–induced anaphylaxis. Rectal temperatures (A) and serum mcpt-1 concentrations (B) in OVA-sensitized WT, Il92/2 , and Il9R2/2 mice injected intravenously with OVA or vehicle (Veh). Fig 4, A and B, n = 4 mice per group from duplicate experiments. *P < .05 compared with WT control.
FIG 5
FIG 5
No role for the IL-9/IL-9R pathway in IgE- or IgG-mediated parenteral OVA-induced systemic anaphylaxis. Rectal maximum temperature changes and serum mcpt-1 concentrations in OVA-sensitized mice desensitized with immunoglobulin control (control Ig; GL117 1 J1.2), anti-IgE mAb, or anti-FcgRII/III mAb and challenged intravenously with OVA are shown. A, WT mice. B, Il92/2 mice. C, Il9R2/2 mice. Data represent means 6 SEMs; n = 3–6 mice per group from duplicate experiments. *P < .05 compared with control Ig.

Similar articles

Cited by

References

    1. Simons FE, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(suppl):S2–S4. - PubMed
    1. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hyper-sensitivity reactions to foods, drugs, and insects. J Allergy Clin Immunol. 2005;116:153–163. - PubMed
    1. Greenberger PA. Drug Allergy. J Allergy Clin Immunol. 2006;117(suppl):S464–S470. - PubMed
    1. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191–193. - PubMed
    1. Wang J, Sampson HA. Food anaphylaxis. Clin Exp Allergy. 2007;37:651–660. - PubMed

Publication types